Researchers at Philip Morris used Myriad RBM’s RodentMAP (Multi-Analyte Profiling) immunoassay service and other histological and functional assessments to demonstrate that prototypic modified risk tobacco product (pMRTP) aerosol stops emphysema progression and eliminates most inflammatory processes when compared to mice exposed to cigarette smoke. The pMRTP investigated is based on a distillation technology with a controlled heating of tobacco rather than burning, yielding a smoke aerosol with reduced concentrations of combustion related constituents. The study provides a framework for future research aiming to identify clinical endpoints and examine the safety of using pMRTPs instead of traditional tobacco alternatives.
